PE20030477A1 - ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents
ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2aInfo
- Publication number
- PE20030477A1 PE20030477A1 PE2002001009A PE2002001009A PE20030477A1 PE 20030477 A1 PE20030477 A1 PE 20030477A1 PE 2002001009 A PE2002001009 A PE 2002001009A PE 2002001009 A PE2002001009 A PE 2002001009A PE 20030477 A1 PE20030477 A1 PE 20030477A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heteroaryl
- phenyl
- inhibitors
- adenosine
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1
- -1 PIPERIDINYL Chemical class 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 1
- QRZMXADUXZADTF-UHFFFAOYSA-N 4-aminoimidazole Chemical compound NC1=CNC=N1 QRZMXADUXZADTF-UHFFFAOYSA-N 0.000 abstract 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 abstract 1
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 1
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 abstract 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 abstract 1
- 229940052760 dopamine agonists Drugs 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A 5-AMINO-IMIDAZOLO[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA SUSTITUIDO DE FORMULA I, DONDE: R ES R1-HETEROARILO, R10-FENILO, -C(=CH2)CH3, CH3, -CH=C(CH3)2, OXAZOL; X ES ALQUILENO C1-C6, COCH2, CONR2CH2; Y ES NR2CH2CH2NR3, OCH2CH2NR2, O, S, CH2S, (CH2)(2-3)-NR2, R5-HETEROARILO, GRUPO a, b, c, Z ES R5-FENILO, ALQUILO C1-C6, R5-HETEROARILO, DIFENILMETILO, R6CO, CUANDO Y ES GRUPO c, Z TAMBIEN ES R6-SO2, R7-NR8CO, R7NR8CS, R6OCO; CUANDO Q ES CH, Z ES FENILAMINO, PIRIDILAMINO; Z E Y SON GRUPOS d, e, ENTRE OTROS O Z E Y FORMAN UN ANILLO PIPERIDINILO, PIRROLIDINILO FUSIONADO A ARILO O HETEROARILO MONOCICLO O BICICLO; X ESTA UNIDO AL N DEL PIPERIDINILO, PIRROLIDINILO; R1 ES H, ALQUILO, CF3, HALOGENO, NO2, NR12R13, ALCOXI, ALQUILTIO, ENTRE OTROS; R2 Y R3 SON H, ALQUILO; m Y n SON 2-3; p Y q SON 0-2; Q Y Q1 SON N, CH, C-CN, COH, C-COCH3; POR LO MENOS UNO DE Q Y Q1 ES N, CH; R4 ES H, ALQUILO, R1-ARILO, R1-HETEROARILO; R5 ES H, HALOGENO, ALQUILO, HIDROXI, ALCOXI, CN, ENTRE OTROS; R6 ES ALQUILO C1-C6, R5-FENILO, TIENILO, ENTRE OTROS; R7 ES ALQUILO, R5-FENILO; R8 ES H, ALQUILO C1-C6, R7 Y R8 JUNTOS SON (CH2)p-A-(CH2)q; p Y q SON 2-3; A ES UN ENLACE, CH2, S, O.TAMBIEN SE REFIERE AL USO CON AGENTES L-DOPA, AGONISTAS DOPAMINERGICOS, INHIBIDORES DE MAO-B, INHIBIDORES DE DOPA DECARBOXILASA, INHIBIDORES COMT. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL COMO PARKINSON
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32956701P | 2001-10-15 | 2001-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030477A1 true PE20030477A1 (es) | 2003-06-06 |
Family
ID=23286007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002001009A PE20030477A1 (es) | 2001-10-15 | 2002-10-11 | ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a |
Country Status (16)
Country | Link |
---|---|
US (1) | US6653315B2 (es) |
EP (1) | EP1435960B1 (es) |
JP (2) | JP4545437B2 (es) |
KR (1) | KR100687954B1 (es) |
CN (1) | CN100421663C (es) |
AR (1) | AR037243A1 (es) |
AU (1) | AU2002340184B2 (es) |
CA (1) | CA2463598C (es) |
HU (1) | HUP0401777A3 (es) |
IL (1) | IL160878A0 (es) |
MX (1) | MXPA04003474A (es) |
MY (1) | MY124864A (es) |
NZ (1) | NZ531761A (es) |
PE (1) | PE20030477A1 (es) |
WO (1) | WO2003032996A1 (es) |
ZA (1) | ZA200402812B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2283625T3 (es) * | 2001-11-30 | 2007-11-01 | Schering Corporation | Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos. |
US20040127510A1 (en) * | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
EP2295047A3 (en) | 2002-12-19 | 2011-05-18 | Schering Corporation | Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders |
AR044041A1 (es) | 2003-04-23 | 2005-08-24 | Schering Corp | Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina |
AU2004244906A1 (en) * | 2003-06-10 | 2004-12-16 | Kyowa Hakko Kirin Co., Ltd. | A method of treating an anxiety disorder |
BRPI0417205A (pt) * | 2003-12-19 | 2007-02-06 | Schering Corp | composições farmacêuticas |
EP1745047B1 (en) | 2004-04-21 | 2010-03-24 | Schering Corporation | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists |
ES2385702T3 (es) * | 2005-06-07 | 2012-07-30 | Kyowa Hakko Kirin Co., Ltd. | Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad |
ATE538123T1 (de) | 2005-09-19 | 2012-01-15 | Schering Corp | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors |
AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
TW200817039A (en) * | 2006-10-06 | 2008-04-16 | Dynamis Therapeutics Inc | Compositions and methods for skin lightening |
EP2125750B1 (en) * | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US7723343B2 (en) * | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
ES2395081T3 (es) * | 2007-07-26 | 2013-02-08 | Vitae Pharmaceuticals, Inc. | Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1 |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
EP2252601B1 (en) | 2008-01-24 | 2012-12-19 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2714532A1 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
WO2009102460A2 (en) * | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
AU2009222047A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists |
CA2718264A1 (en) * | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
US8242111B2 (en) * | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
ES2421537T3 (es) | 2008-05-01 | 2013-09-03 | Vitae Pharmaceuticals Inc | Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 |
US8569292B2 (en) | 2008-05-01 | 2013-10-29 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
JP5777030B2 (ja) | 2008-07-25 | 2015-09-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤 |
PL2324018T3 (pl) | 2008-07-25 | 2014-02-28 | Boehringer Ingelheim Int | Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1 |
EP2393807B1 (en) | 2009-02-04 | 2013-08-14 | Boehringer Ingelheim International GmbH | Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
GEP20156309B (en) * | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
JP5656986B2 (ja) | 2009-06-11 | 2015-01-21 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 1,3−オキサジナン−2−オン構造に基づく11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
KR102653800B1 (ko) | 2018-11-30 | 2024-04-01 | 머크 샤프 앤드 돔 엘엘씨 | 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0217748B1 (en) | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
JPH06104666B2 (ja) * | 1986-09-30 | 1994-12-21 | チバ―ガイギー アクチェンゲゼルシャフト | 2―置換―e―縮合―〔1,2,4〕トリアゾロ〔1,5―c〕ピリミジン類及びそれを含有する医薬組成物 |
IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
EP0666079B1 (en) * | 1993-07-27 | 2001-11-07 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for parkinson's disease |
IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
IT1291372B1 (it) * | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
CA2326716C (en) | 1998-04-03 | 2006-12-12 | Otsuka Pharmaceutical Factory, Inc. | Triazolopurine derivative, pharmaceutical composition containing the derivative, adenosine a3 receptor ligand, and remedy for asthma |
ATE265459T1 (de) | 1999-09-28 | 2004-05-15 | Otsuka Pharma Co Ltd | Triazolpurin-derivate, medikamentzusammensetzungen, die diese enthalten und mittel, die affinität zum adenosin a3 rezeptor zeigen |
MY132006A (en) | 2000-05-26 | 2007-09-28 | Schering Corp | ADENOSINE A2a RECEPTOR ANTAGONISTS |
JP4284182B2 (ja) | 2001-11-30 | 2009-06-24 | シェーリング コーポレイション | アデノシンA2aレセプターアンタゴニスト |
-
2002
- 2002-10-11 MX MXPA04003474A patent/MXPA04003474A/es active IP Right Grant
- 2002-10-11 US US10/269,754 patent/US6653315B2/en not_active Expired - Lifetime
- 2002-10-11 NZ NZ531761A patent/NZ531761A/en unknown
- 2002-10-11 CN CNB028203283A patent/CN100421663C/zh not_active Expired - Fee Related
- 2002-10-11 HU HU0401777A patent/HUP0401777A3/hu unknown
- 2002-10-11 CA CA002463598A patent/CA2463598C/en not_active Expired - Fee Related
- 2002-10-11 AR ARP020103834A patent/AR037243A1/es unknown
- 2002-10-11 IL IL16087802A patent/IL160878A0/xx unknown
- 2002-10-11 KR KR1020047005369A patent/KR100687954B1/ko not_active IP Right Cessation
- 2002-10-11 MY MYPI20023804A patent/MY124864A/en unknown
- 2002-10-11 PE PE2002001009A patent/PE20030477A1/es not_active Application Discontinuation
- 2002-10-11 EP EP02778530.2A patent/EP1435960B1/en not_active Expired - Lifetime
- 2002-10-11 JP JP2003535799A patent/JP4545437B2/ja not_active Expired - Fee Related
- 2002-10-11 AU AU2002340184A patent/AU2002340184B2/en not_active Ceased
- 2002-10-11 WO PCT/US2002/032630 patent/WO2003032996A1/en active IP Right Grant
-
2004
- 2004-04-13 ZA ZA200402812A patent/ZA200402812B/en unknown
-
2008
- 2008-07-25 JP JP2008192667A patent/JP2008297312A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4545437B2 (ja) | 2010-09-15 |
ZA200402812B (en) | 2005-04-25 |
HUP0401777A3 (en) | 2008-06-30 |
JP2008297312A (ja) | 2008-12-11 |
WO2003032996A1 (en) | 2003-04-24 |
CA2463598C (en) | 2009-09-08 |
JP2005506352A (ja) | 2005-03-03 |
MY124864A (en) | 2006-07-31 |
NZ531761A (en) | 2005-10-28 |
CN100421663C (zh) | 2008-10-01 |
CN1612736A (zh) | 2005-05-04 |
MXPA04003474A (es) | 2004-07-30 |
AU2002340184B2 (en) | 2005-10-06 |
US20030171381A1 (en) | 2003-09-11 |
CA2463598A1 (en) | 2003-04-24 |
EP1435960B1 (en) | 2014-07-30 |
HUP0401777A2 (hu) | 2004-12-28 |
AR037243A1 (es) | 2004-11-03 |
KR20050035155A (ko) | 2005-04-15 |
EP1435960A1 (en) | 2004-07-14 |
IL160878A0 (en) | 2004-08-31 |
KR100687954B1 (ko) | 2007-02-27 |
US6653315B2 (en) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030477A1 (es) | ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
PE20020062A1 (es) | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a | |
PE20030665A1 (es) | ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
PE20081192A1 (es) | Tratamiento del dolor | |
PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
PE20030975A1 (es) | 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS | |
PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
PE20030415A1 (es) | Derivados policiclicos de guanina como inhibidores de fosfodiesterasa v | |
AR030186A1 (es) | Compuesto antibacteriano 3-aminoquinazolina-2,4-diona, composicion farmaceutica que lo comprende y su uso para fabricarla | |
PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
PE20061424A1 (es) | Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
PE20010964A1 (es) | Derivados de tiazolilamida | |
PE20030431A1 (es) | DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7 | |
PE20030653A1 (es) | COMPUESTOS BICICLICOS[1,2,4]-TRIAZOL COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a | |
PE20020470A1 (es) | Derivados de pirazol como inhibidores de las enzimas proteina quinasas | |
PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
PE20030848A1 (es) | Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 | |
PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
PE20030603A1 (es) | Derivados de quinolina | |
PE20100737A1 (es) | Nuevos compuestos | |
PE20080744A1 (es) | IMIDAZOL AMINAS COMO INHIBIDORES DE LA ß-SECRETASA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |